

Table 14-7.04
Summary of Concomitant Medications (Number of Subjects)

Therapeutic class, n (%)	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)
Patients receiving at least one concomitant medication	77 (90%)	74 (88%)	78 (93%)
ALIMENTARY TRACT AND METABOLISM	12 (14%)	11 (13%)	9 (11%)
CALCIUM	7 (8%)	6 (7%)	3 (4%)
ALGELDRATE	2 (2%)	0	2 (2%)
LOPERAMIDE HYDROCHLORIDE	1 (1%)	1 (1%)	1 (1%)
METFORMIN HYDROCHLORIDE	1 (1%)	1 (1%)	0
NIZATIDINE	1 (1%)	1 (1%)	4 (5%)
CALCIUM CARBONATE	0	0	1 (1%)
CIMETIDINE	0	1 (1%)	0
SIMETICONE	0	2 (2%)	0
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	1 (1%)	0	1 (1%)
LEUPRORELIN ACETATE	1 (1%)	0	1 (1%)
BLOOD AND BLOOD FORMING ORGANS	0	1 (1%)	0
FERROUS SULFATE	0	1 (1%)	0
CARDIOVASCULAR SYSTEM	12 (14%)	12 (14%)	7 (8%)
AMLODIPINE	8 (9%)	1 (1%)	2 (2%)
FUROSEMIDE	2 (2%)	2 (2%)	1 (1%)
NIFEDIPINE	2 (2%)	0	0
DOXAZOSIN MESILATE	1 (1%)	2 (2%)	1 (1%)
DIGOXIN	0	3 (4%)	2 (2%)
DILTIAZEM HYDROCHLORIDE	0	0	1 (1%)
FELODIPINE	0	1 (1%)	0
FLUVASTATIN	0	2 (2%)	0
LOSARTAN POTASSIUM	0	2 (2%)	0
DERMATOLOGICALS	0	0	1 (1%)

Table 14-7.04
Summary of Concomitant Medications (Number of Subjects)

Therapeutic class, n (%)	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)
CLOBETASOL PROPIONATE	0	0	1 (1%)
GENITO URINARY SYSTEM AND SEX HORMONES	6 (7%)	10 (12%)	5 (6%)
ESTROGENS CONJUGATED	6 (7%)	10 (12%)	5 (6%)
NERVOUS SYSTEM	23 (27%)	14 (17%)	8 (10%)
ACETYLSALICYLIC ACID	21 (24%)	11 (13%)	6 (7%)
ALPRAZOLAM	1 (1%)	0	0
DONEPEZIL HYDROCHLORIDE	1 (1%)	2 (2%)	2 (2%)
SUMATRIPTAN	1 (1%)	0	0
HALOPERIDOL	0	1 (1%)	0
PAROXETINE HYDROCHLORIDE	0	1 (1%)	0
RESPIRATORY SYSTEM	4 (5%)	1 (1%)	4 (5%)
SALBUTAMOL SULFATE	2 (2%)	1 (1%)	0
GUAIFENESIN	1 (1%)	0	0
IPRATROPIUM BROMIDE	1 (1%)	0	0
NAPROXEN SODIUM	1 (1%)	0	3 (4%)
BUDESONIDE	0	0	1 (1%)
SYSTEMIC HORMONAL PREPARATIONS, EXCL.	2 (2%)	13 (15%)	8 (10%)
HYDROCORTISONE	2 (2%)	13 (15%)	8 (10%)
UNCODED	74 (86%)	70 (83%)	77 (92%)
UNCODED	74 (86%)	70 (83%)	77 (92%)